Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 8Multiple Myeloma 2Carcinoma, Ovarian Epithelial 2Recurrence 1Peritoneal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1Advanced Malignancies 1

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × 1-dodecylpyridoxal × Clear all
NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Shattuck Labs, Inc.

Phase 1 Completed
86 enrolled 17 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01004380 2014-07-17

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Morphotek

Phase 1 Completed
15 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡